Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the United States. Although there have been numerous advances in our understanding of pancreatic cancer development and progression in recent years, therapies for pancreatic cancer generally still provide only modest benefit. Surgical resection is currently the most effective treatment but is undertaken in only ∼15--20% of patients highlighting the need for early detection strategies. Even among patients with resectable pancreatic cancer survival is poor, with \<20% of patients alive at 5 years Among patients undergoing pancreatic resection with curative intent, the main prognostic factors are histological grade, resection margin status, tumour size, location and lymph node metastasis ([@bib46]; [@bib10]; [@bib16]; [@bib14] (in press); [@bib44] (in press)).

Although very useful, these pathological risk factors do not sufficiently predict outcome and most of these prognostic factors reflect tumour stage rather than tumour epithelial biology. Multiple studies have attempted to identify markers that may assist in predicting outcome after pancreatic cancer resection and that may also provide clues as to biological mechanisms that contribute to pancreatic cancer aggressiveness. For example, mutations or loss of expression of tumour-suppressor proteins expressed by tumour epithelial cells such as Smad4 ([@bib42]; [@bib2]; [@bib3]; [@bib20]), or patterns of stromal fibroblast-expressed proteins such as Sparc have been shown to predict outcome ([@bib39]; [@bib21]).

Vimentin is expressed by normal mesenchymal tissue and is considered a marker of mesenchymal differentiation ([@bib28]). Vimentin is an intermediate-sized filament polypeptide, which along with desmin, keratin, glial acidic protein and neurofilament intermediate filaments are distinguished by their chemical characteristics, immunological specificities and cell-type distribution ([@bib11]; [@bib27]). Epithelial neoplasms can occasionally express both cytokeratin and vimentin, features often associated with the acquisition of mesenchymal histologic features. There is evidence that carcinomas with markers of mesenchymal differentiation have different biological and clinical behaviour ([@bib12],[@bib13]; [@bib34]; [@bib30]). Pancreatic cancer vimentin expression patterns have been investigated in small series. [@bib40] reported a lack of expression in pancreatic cancers, while [@bib36]) observed sparse cell labelling in 30 primary pancreatic adenocarcinomas with prominent expression in 15 liver metastases. Similarly, vimentin labelling was more pronounced in widely metastatic pancreatic cancers as compared with locally destructive ones ([@bib35]). Khoury *et al* found that vimentin expression in 34 pancreatic cancers correlated with poor survival ([@bib23]). Interestingly, although mesenchymal differentiation is associated with reduced E-cadherin expression *in vitro*, in liver metastasis of pancreatic ductal adenocarcinomas [@bib36]) found a correlation between vimentin expression and N-cadherin but not E-cadherin expression. More recent reports suggest that, *in vitro,* most pancreatic cancers with well-defined glandular differentiation do not show the downregulation of E-cadherin, although focal loss of E-cadherin expression is observed in some primary pancreatic cancers ([@bib29]; [@bib18] (in press)) and undifferentiated pancreatic cancers often display complete loss of E-cadherin expression ([@bib47]).

In this study, we investigated vimentin expression in a large series of pancreatic ductal adenocarcinomas treated by surgery and assessed its relationship to survival.

Patients and Methods
====================

Patients and samples
--------------------

Patients having conventional pancreatic ductal adenocarcinoma ([@bib24]), treated by surgical resection were retrieved from the database of the Pathology Department, of the Johns Hopkins Medical Institutions, Baltimore, MD, USA. Between 1998 and 2006, 387 patients had available neoplastic tissue blocks to construct tissue microarrays.

This study was designed and performed according to current recommendations for tumour markers ([@bib33]). The patients were analysed for clinical and pathological data according to standard criteria ([@bib24]; [@bib1]). The clinical data analysed included: age, gender, date of surgery, type of surgery, stage, date of death or last consultation for the postsurgical survival. As information on adjuvant therapy was not complete for some patients who received their postoperative therapy at other centres, postoperative therapy was not included in the analysis of the prognostic significance of vimentin. The analysed pathological data were: tumour size, histological differentiation, vascular invasion, perineural invasion, pathological T TMN stage, lymph node metastases and N TMN stage as well as for distant metastases (M TNM stage). As their outcome is significantly different patients were excluded if they had a peri-operative death (occurring within the first 30 days postoperatively, 4 patients) or with follow-up of \<30 days (28 patients), a distal splenopancreatectomy (1 patients) or if they received neoadjuvant radiotherapy (2 patients).

Immunohistochemistry
--------------------

Vimentin protein expression was assessed in the tumour epithelial tissues by immunohistochemistry. Tissue microarrays were constructed from representative areas of neoplastic epithelial cells and normal pancreas as previously described ([@bib21]; [@bib31]; [@bib45]). Each patient\'s tissue was represented on the tissue microarrays by two cores of pancreatic cancer and two cores of non-neoplastic pancreas.

Immunohistochemistry was performed using an antibody to vimentin protein (Dakocytomation, Carpinteria, CA, USA, clone V9, dilution 1 : 200). Protein expression in the cytoplasm or peri-membrane and membrane in epithelial malignant cells setting was assessed by an experienced pancreatic pathologist (AHL) at an Olympus BX51 microscope (Olympus, Center Valley, PA, USA). The percentage of labelled tumour epithelial cells was determined. Spindle-shaped isolated cells with bland, regular nucleus were considered as stromal fibroblasts. Representative neoplastic zones were photographed and were included in the figures (Photo Olympus DP20). For 14 patients, there were no data on vimentin neoplastic cell expression because of tissue loss during the immunolabelling protocol. For each neoplasm, the core with the highest expression of vimentin was taken into consideration for subsequent statistical analysis. The percentage of labelled neoplastic epithelial cells ranged from 0 to 95%.

Statistical analysis
--------------------

For the statistical analysis, the variables were considered as categorical. For continuous variables such as tumour size or lymph node metastases, the cutoff for classifying the tumours was the median. We also determined the median percentage of vimentin-expressing neoplastic cells, which was 1% and used this as a cutoff for classifying cancers. We also evaluated other cutoffs (0, 10, 20, 30, 40, 50, 60, 70, 80 and 90%). According to the distribution of the percentage of vimentin-expressing neoplastic cells in this series of tumours, the cutoff of 10% was accepted as most predictive. The relationships between clinico--morphological variables and the expression of vimentin by neoplastic cells were analysed by using the Fisher\'s or *χ*^2^-tests (Medcalc v11.1.1 software, Medcalc, Mariakerke, Belgium). For univariate survival analysis we used the Kaplan--Meier method, the survival curves being compared by the log-rank test. For multivariate survival analysis we used the Cox method. Variables found on univariate analysis to be related to postsurgical survival with a *P*-value of \<0.05 were included in Cox models. Colinearity (redundancy) of variables being significantly correlated on Fisher\'s or *χ*^2^-tests was tested (neoplastic differentiation and vimentin expression, microscopic vascular expression and lymph node metastases, tumour size and type of surgery). Patients with unavailable data were included in the analysis as 'unknown\'. For all the statistical tests and methods, a *P*-value of \<0.05 was used for defining statistical significance ([@bib8]; [@bib6]; [@bib19]).

Results
=======

Patients\' and tumour characteristics
-------------------------------------

The patients\' demographics are listed in [Table 1](#tbl1){ref-type="table"}. The median follow-up was 14.4 months (range, 1.1--101.95 months). During the study period, 246 patients died (excluding patients with perioperative death) and the median survival was 14.4 months and the time to death was 12.90 months (range, 1.21--59.24 months). The 3-year postsurgical survival was 19.32% and the 5-year survival 8.0%.

Median tumour size was 30 mm (range, 10--120 mm). Tumour size was significantly higher in those patients having total pancreatectomy surgery as compared with those treated by pancreaticoduodenectomy (*P*=0.04). Lymph node metastases were observed in 85.7% of the patients with the median number of metastatic lymph nodes being 3 (range, 1--25). The presence of lymph node metastases was correlated to vascular and perineural invasion (*P*\<0.01 and *P*=0.05, respectively), whereas presence of \>3 lymph node metastases was correlated to vascular invasion and increased neoplastic size (*P*\<0.01 and *P*=0.02, respectively). Three patients showed distant metastasis (pericaval, mesocolon and subcostal skin metastases, respectively).

Vimentin expression by pancreatic cancer cells
----------------------------------------------

Vimentin expression by the neoplastic cells was observed in 154 (45%) pancreatic ductal adenocarcinomas ([Figure 1](#fig1){ref-type="fig"}), and included a wide variation in the extent of cancer cell expression varying from 1 to 95%, with the median percentage of vimentin-labelled cancer cells being 1%. In 94 pancreatic cancers (27.5%), vimentin was expressed in \>10% of neoplastic cells. There was not a specific labelling pattern, vimentin being expressed by cells with varying degrees of cytonuclear atypia, with or without intracellular mucus, forming neoplastic glands or masses or disposed isolated within the stroma. When analysed with regard to the morphological features of the neoplasm, the expression of vimentin by neoplastic cells was significantly correlated only with poor histological differentiation (using the vimentin cutoff of 1%, 76 of 148 poorly differentiated cancers compared with 78 of 194 well and moderately differentiated cancers; using the vimentin cutoff of 10%, 53 of 143 poorly differentiated neoplastic cells *vs* 41 of 194 well and moderately differentiated cancers) (*P*=0.05 and *P*\<0.01 for vimentin cutoffs 1% and 10%, respectively). There was no statistical difference in neoplastic cell vimentin expression between early-stage (stages T1 or T2 TNM) and advanced tumours (TNM stages T3 or T4). By univariate survival analysis ([Table 1](#tbl1){ref-type="table"}), patients\' outcome was correlated with poor histological differentiation, positive tumour resection margins, the presence of lymph node metastases, increased tumour size and tumour epithelial vimentin expression. The statistical significance of the relationship between tumour epithelial vimentin expression and a shorter postsurgical survival was more important when considering the cutoff of 10% (*P*\<0.01, median postsurgical survivals 12.49 *vs* 19.72 months) ([Figure 2](#fig2){ref-type="fig"}) than for the cutoff of 1% (*P*=0.02, median postsurgical survivals 15.05 *vs* 19.52 months). By multivariate survival analysis ([Table 2](#tbl2){ref-type="table"}), tumour epithelial vimentin expression was significantly related to a shorter postsurgical survival, independently of the degree of histological differentiation, surgical margin status, tumour size (\>30 mm) and lymph node metastases. In this model, high (\>10%) tumour epithelial vimentin expression was a more powerful predictor of outcome than the N TNM stage, the type of surgery, and tumour size, the risk of death being 1.53.

High tumour epithelial vimentin expression correlated with 3- and 5-year survival (*P*\<0.01 for both comparisons) as well as tumour size (*P*=0.03 and *P*=0.05), N TNM stage (*P*\<0.01 and *P*=0.03), differentiation (*P*\<0.01 for both comparisons), surgery type (*P*=0.03 and *P*=0.05), and margin status (*P*\<0.01 and *P*=0.02).

The association of positive vimentin expression with a shorter survival remained among the main subgroups of patients studied including those treated by pancreaticoduodenectomy, with T3 stage cancers, those patients with lymph node metastasis (N1 TNM stage) and those patients having margin negative, stage 2 or stage 2B disease or in those patients having cancers with moderate or poor differentiation ([Table 3](#tbl3){ref-type="table"}) ([Figure 3](#fig3){ref-type="fig"}).

Similarly, in the group of patients having cancers with high vimentin expression (\>10% of cancer cells expressing), margin-positive surgical resection (*P*=0.04) and tumour size (*P*=0.04) were also predictors of a shorter postsurgical survival.

Discussion
==========

Our analysis of a large series of pancreatic adenocarcinomas treated by surgical resection indicated that tumour epithelial vimentin expression is an indicator of adverse outcome both on univariate and multivariate survival analysis, independently of classical tumour characteristics such as differentiation, tumour size, resection margin status and type of surgical treatment.

The most powerful predictors of a shorter postsurgical survival in our series were positive margin status and poor histological differentiation, in agreement with the results of [@bib16]), and [@bib46]), in previous studies from our institution. We also found that lymph node metastasis predicted a shorter postsurgical survival, consistent with already reported results ([@bib46]; [@bib21]; [@bib5]).

Vimentin expression by neoplastic cells was observed in 45% of the pancreatic adenocarcinomas and an expression level of \>10% was noted in 27.5% of the pancreatic cancers. We found this 10% cutoff to be more predictive of outcome than other cutoffs of percentage expression or the absolute cutoff (of presence *vs* absence of neoplastic cell expression). Although the expression concerned a limited percentage of neoplastic cells in some tumours, vimentin was significantly related to postsurgical survival. The association of vimentin expression to a shorter survival had a greater prognostic significance than that of N TNM stage, tumour size, and of almost as much magnitude as other prognostic factors such as differentiation and surgical margin ([@bib46]; [@bib16]; [@bib5]).

The underlying biological mechanisms that might explain the relationship between vimentin and survival are not known. As has been previously reported for breast and prostatic adenocarcinomas ([@bib12],[@bib13]; [@bib15]; [@bib48]), we found a correlation between vimentin expression and histological differentiation. Previous studies have found associations between vimentin expression and cancer cell morphology in tumour xenografts ([@bib37]). Vimentin expression in neoplastic epithelial cells might reflect a reorganisation of cytoplasmic intermediate filaments, which could be related to poor differentiation. However, poor differentiation is more complex than cytoplasmic changes since it involves also nuclear changes. Although vimentin expression is associated with poor differentiation in cancers, in our series vimentin expression is still an independent predictor of outcome after accounting for the degree of differentiation suggesting vimentin expression is a marker for more than differentiation. Whether or not vimentin expression directly affects the aggressiveness of pancreatic cancer cells because of its functional effects as an intermediate filament or whether it is merely a marker of a more aggressive cancer cell is not known. Studies of peripheral blood mononuclear cells as well as of human breast, colon and prostate cancer cell lines suggest a cell-type-specific role for vimentin in cell adhesion, motility and invasiveness ([@bib38]; [@bib22]; [@bib32]; [@bib48]). Vimentin\'s functions are influenced by cell signalling pathways such as AKT and STK33 that result in vimentin phosphorylation ([@bib22]; [@bib4]; [@bib49]). Vimentin phosphorylation contributes to disassembly of vimentin polymers diminishing its function as an intermediate filament and influencing its protein--protein interactions. Vimentin also undergoes proteolysis by caspases when cells receive pro-apoptotic stimuli ([@bib26]). Recently vimentin has evolved as a marker of 'epithelial--mesenchymal transdifferentiation\' and many molecular alterations have been implicated in this process including Notch, miR-200 and others ([@bib25]). Cancer cell vimentin expression has also been found to influence treatment response *in vitro*. For example, gemcitabine-resistant pancreatic cancer cells display increased vimentin expression ([@bib43]), and vimentin expression increased in Panc-1 cell lines when treated by TGFbeta ([@bib36]). Vimentin has been investigated as a therapeutic target. A natural compound, withaferin-A-induced vimentin degradation and slowed the growth of sarcomas and had proapoptotic effects in sarcoma and carcinoma cell lines expressing vimentin ([@bib26]).

In recent years, vimentin expression has been commonly used as a marker of mesenchymal phenotypes but this intermediate filament has complex functions including its affinity to single-stranded and supercoiled DNA and its strong tendency to interact with different chromatin constituents including histones ([@bib43]). However, mice lacking vimentin do not have altered phenotypes so the functional significance of vimentin expression is not well understood ([@bib9]).

As vimentin is highly expressed in stromal fibroblasts it is not likely to be useful as a marker for differentiating pancreatic cancers from pancreatitis, but interestingly autoantibodies to this protein have been recently reported ([@bib17]). Pancreatic neoplastic tissues showed a three-fold higher expression of vimentin than neoplasms of other origins (lung, colon and ovary), and had higher levels of an isoform with demonstrable immunogenicity ([@bib17]). More promising as a marker of neoplasia is vimentin promoter methylation, which is being evaluated as a candidate marker of colorectal carcinomas ([@bib7]; [@bib50]; [@bib41]).

There are a number of limitations to our study that should be acknowledged. First, our study is a single-centre study, and confirmation of our findings in other series is warranted. Second, our prognostic model did not include postoperative therapy in our model as unlike surgical therapy, postoperative therapy is not uniform in our study population. Although our cases were not selected with regard to their postoperative course, it is possible that the association between tumour epithelial vimentin expression and outcome of pancreatic cancer could be influenced by differences in postoperative chemoradiotherapy.

In conclusion, the results of our study suggest that *de novo* tumour epithelial expression of vimentin in pancreatic ductal adenocarcinoma is an independent predictor of adverse postsurgical outcome.
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![Vimentin protein expression in primary pancreatic adenocarcinoma cells: the figure on the left (**A**) shows minimal vimentin expression in a few pancreatic cancer cells (arrow), vimentin also being expressed in stromal fibroblasts (considered as internal control, arrowheads). On the right side (**B**) there is pancreatic adenocarcinoma showing uniform cytoplasmic and perimembrane pattern of vimentin expression (arrow) (original magnification × 30).](bjc201193f1){#fig1}

![Kaplan--Meier curves for postsurgical survival according to tumour epithelial vimentin expression when considering the cutoff of 1% (**A**) and that of 10% (**B**). The continuous line indicates the patients with high vimentin (\>1 or \>10%) expression whereas the discontinuous lines those patients with low vimentin expression.](bjc201193f2){#fig2}

![Kaplan--Meier curves for postsurgical survival according to tumour epithelial vimentin expression when considering varied groups of patients: groups of patients treated by pancreaticoduodenectomy (**A**), patients with pathological T3 TNM stage (**B**), patients with tumour-free surgical resection (**C**) as well as patients with stage 2 disease (**D**). The continuous line indicates the patients with high vimentin (\>10%) expression whereas the discontinuous lines those patients with low vimentin expression.](bjc201193f3){#fig3}

###### Clinico--pathological characteristics of the patients with pancreatic ductal adenocarcinomas treated by surgical resection

                              **Number of patients *n*=356[a](#t1-fn2){ref-type="fn"}**  **Median postsurgical survival (months)**   **Log-rank *P***
  -------------------------- ----------------------------------------------------------- ------------------------------------------- ------------------
  *Gender*                                              0.83                                                                         
   Women                                                 160                             16.76                                        
   Men                                                   196                             18.08                                        
                                                                                                                                      
  *Age (years)*                                                                                                                      
   Range                                               32--90                                                                         
   Median                                               66.66                                                                         
                                                                                                                                      
  *Outcome*                                                                                                                          
   Follow-up                                            14.4                                                                          
   Range, months                                    1.08--101.95                                                                      
   Median, months                                                                        14.4                                         
   Dead                                                  246                                                                          
   Alive                                                 110                                                                          
                                                                                                                                      
  *T Stage*                                             0.12                                                                         
   pT1                                                    4                              ---                                          
   pT2                                                    7                              17.44                                        
   pT3                                                   336                             17.98                                        
   pT4                                                    9                              10.29                                        
                                                                                                                                      
  *Differentiation*                                    \<0.01                                                                        
   Well, moderate                                        199                             21.89                                        
   Poor                                                  157                             13.01                                        
                                                                                                                                      
  *Vascular invasion*                                   0.02                                                                         
   Absent                                                170                             20.38                                        
   Present                                               176                             15.32                                        
   Indeterminate                                         10                              12.82                                        
                                                                                                                                      
  *Surgery type*                                        0.04                                                                         
   Pancreaticoduodenectomy                               335                             17.98                                        
   Total pancreatectomy                                  21                              10.75                                        
                                                                                                                                      
  *Tumour size*                                         0.02                                                                         
   Range, median                                                                                                                      
   30 mm                                                 217                             19.59                                        
   \>30 mm                                               139                             14.66                                        
                                                                                                                                      
  *Surgical margins*                                   \<0.01                                                                        
   Non-tumoral                                           238                             20.31                                        
   Tumoral                                               118                             14                                           
                                                                                                                                      
  *Lymph node metastasis*                                                                                                            
   *N TNM stage*                                        0.01                                                                         
    N0                                                   51                              26.4                                         
    N1                                                   305                             16.63                                        

Abbreviations: *n*=number of patients; *N*=node; T=tumour; p=pathology; TNM=tumour node metastasis classification.

Patients with perioperative death (within the 30 days after surgery), were not included for the statistical analysis.

###### Cox model including as variables tumour and surgical resection parameters

                               ***P*-value**   **Hazard ratio**    **95% confidence interval**
  ---------------------------- --------------- ------------------ -----------------------------
  Differentiation              \<0.01          1.54                       1.20 to 1.96
  Surgical margin status       \<0.01          1.62                       1.24 to 2.12
  Tumour vimentin expression   \<0.01          1.53                       1.14 to 2.05
  Type of surgery              0.03            1.81                       1.07 to 3.08
  N TNM stage                  0.05            1.48                       1.00 to 2.18
  Tumour size, \>3 mm          0.14            1.22                       0.94 to 1.59

Abbreviations: *N*=node; TNM=tumour node metastasis classification.

###### Univariate survival analysis for vimentin expression in pancreatic ductal adenocarcinomas

                                                                                           **Median postsurgical survival (months)**   **Log-rank *P-*value**
  ---------------------------------------------------------------------------------------- ------------------------------------------- ------------------------
  *Patients treated by pancreaticoduodenectomy (*n*=322)*                                  \<0.01                                      
   Low tumour vimentin                                                                     19.72                                        
   High tumour vimentin                                                                    12.82                                        
                                                                                                                                        
  *T3 TNM stage patients (*N*=322)*                                                        \<0.01                                      
   Low tumour vimentin                                                                     20.35                                        
   High tumour vimentin                                                                    12.49                                        
                                                                                                                                        
  *N1 TNM stage patients (*N*=293)*                                                        \<0.01                                      
   Low tumour vimentin                                                                     19.29                                        
   High tumour vimentin                                                                    12.09                                        
                                                                                                                                        
  *Stage 2 patients (AJCC 7) (*N*=328)*                                                    \<0.01                                      
   Low tumour vimentin                                                                     20.38                                        
   High tumour vimentin                                                                    12.49                                        
                                                                                                                                        
  *Stage 2B patients (AJCC 7) (*N*=279)*                                                   \<0.01                                      
   Low tumour vimentin                                                                     20.35                                        
   High tumour vimentin                                                                    12.29                                        
                                                                                                                                        
  *Patients with margin negative surgical resections (*N*=230)*                            0.02                                        
   Low tumour vimentin                                                                     14.95                                        
   High tumour vimentin                                                                    10.25                                        
                                                                                                                                        
  *Patients having tumours with moderate or poor histological differentiation (*N*=332)*   \<0.01                                      
   Low tumour vimentin                                                                     19.46                                        
   High tumour vimentin                                                                    12.49                                        

Abbreviations: AJCC=American Joint Committee on Cancer; *n*=number of patients.
